Last reviewed 2026-06-02 · How we verify

Adjunctive asenapine

Lori Davis, MD · FDA-approved active Small molecule

Adjunctive asenapine is a Atypical antipsychotic Small molecule drug developed by Lori Davis, MD. It is currently FDA-approved for Adjunctive treatment of bipolar I disorder in adults, Adjunctive treatment of major depressive disorder in adults. Also known as: asenapine, Saphris.

Asenapine is an atypical antipsychotic that blocks dopamine and serotonin receptors in the brain to reduce psychotic symptoms and mood disturbances.

Asenapine is an atypical antipsychotic that blocks dopamine and serotonin receptors in the brain to reduce psychotic symptoms and mood disturbances. Used for Adjunctive treatment of bipolar I disorder in adults, Adjunctive treatment of major depressive disorder in adults.

At a glance

Generic name	Adjunctive asenapine
Also known as	asenapine, Saphris
Sponsor	Lori Davis, MD
Drug class	Atypical antipsychotic
Target	D2 dopamine receptor, 5-HT2A serotonin receptor
Modality	Small molecule
Therapeutic area	Psychiatry
Phase	FDA-approved

Mechanism of action

Asenapine acts as an antagonist at multiple dopamine receptors (D2, D3) and serotonin receptors (5-HT2A, 5-HT7), with particular affinity for D2 and 5-HT2A. When used adjunctively, it enhances the therapeutic effect of other psychiatric medications by providing additional dopaminergic and serotonergic modulation, helping to stabilize mood and reduce psychotic or manic symptoms in patients with inadequate response to monotherapy.

Approved indications

Adjunctive treatment of bipolar I disorder in adults
Adjunctive treatment of major depressive disorder in adults

Common side effects

Akathisia
Somnolence
Weight gain
Extrapyramidal symptoms
Dizziness
Oral hypoesthesia

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Adjunctive asenapine CI brief — competitive landscape report
Adjunctive asenapine updates RSS · CI watch RSS
Lori Davis, MD portfolio CI

Frequently asked questions about Adjunctive asenapine

What is Adjunctive asenapine?

Adjunctive asenapine is a Atypical antipsychotic drug developed by Lori Davis, MD, indicated for Adjunctive treatment of bipolar I disorder in adults, Adjunctive treatment of major depressive disorder in adults.

How does Adjunctive asenapine work?

Asenapine is an atypical antipsychotic that blocks dopamine and serotonin receptors in the brain to reduce psychotic symptoms and mood disturbances.

What is Adjunctive asenapine used for?

Adjunctive asenapine is indicated for Adjunctive treatment of bipolar I disorder in adults, Adjunctive treatment of major depressive disorder in adults.

Who makes Adjunctive asenapine?

Adjunctive asenapine is developed and marketed by Lori Davis, MD (see full Lori Davis, MD pipeline at /company/lori-davis-md).

Is Adjunctive asenapine also known as anything else?

Adjunctive asenapine is also known as asenapine, Saphris.

What drug class is Adjunctive asenapine in?

Adjunctive asenapine belongs to the Atypical antipsychotic class. See all Atypical antipsychotic drugs at /class/atypical-antipsychotic.

What development phase is Adjunctive asenapine in?

Adjunctive asenapine is FDA-approved (marketed).

What are the side effects of Adjunctive asenapine?

Common side effects of Adjunctive asenapine include Akathisia, Somnolence, Weight gain, Extrapyramidal symptoms, Dizziness, Oral hypoesthesia.

What does Adjunctive asenapine target?

Adjunctive asenapine targets D2 dopamine receptor, 5-HT2A serotonin receptor and is a Atypical antipsychotic.

Drug class: All Atypical antipsychotic drugs
Target: All drugs targeting D2 dopamine receptor, 5-HT2A serotonin receptor
Manufacturer: Lori Davis, MD — full pipeline
Therapeutic area: All drugs in Psychiatry
Indication: Drugs for Adjunctive treatment of bipolar I disorder in adults
Indication: Drugs for Adjunctive treatment of major depressive disorder in adults
Also known as: asenapine, Saphris

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing